NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
088 Region Stockholm

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 498 7.9% 177 2.8% 104 1.6% 1 0.0% 3 0.0% 26 0.4% 5508 87.2% 6317 100.0%
ASCUS 647 33.2% 411 21.1% 276 14.2% 15 0.8% 4 0.2% 31 1.6% 564 29.0% 1948 100.0%
LSIL 387 29.6% 360 27.6% 249 19.1% 1 0.1% . . 12 0.9% 297 22.7% 1306 100.0%
Atypical glandular cells/AGC 24 20.7% 21 18.1% 45 38.8% 9 7.8% 4 3.4% 3 2.6% 10 8.6% 116 100.0%
Unclear atypia 1 16.7% 1 16.7% 1 16.7% . . . . . . 3 50.0% 6 100.0%
ASC-H 47 18.5% 47 18.5% 128 50.4% 4 1.6% 2 0.8% . . 26 10.2% 254 100.0%
HSIL 35 9.8% 36 10.1% 217 60.8% 3 0.8% 5 1.4% 3 0.8% 58 16.2% 357 100.0%
Suspected Adenocarcinom 1 5.0% . . 2 10.0% 4 20.0% 4 20.0% . . 9 45.0% 20 100.0%
Malignant tumor with unclear origin . . . . 1 100.0% . . . . . . . . 1 100.0%
Squamous cell cancer . . . . 1 50.0% . . 1 50.0% . . . . 2 100.0%
Totalt 1640 15.9% 1053 10.2% 1024 9.9% 37 0.4% 23 0.2% 75 0.7% 6475 62.7% 10327 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category Cancer:
M69760, M80703, M81403, M82003, M85603